All News

14 April 2008

Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine’s anti-PS Vascular Targeting AntibodiesAntibodies

14 April 2008

Lpath Submits Investigational New Drug Application for iSONEP(TM)Antibodies

13 April 2008

U3 Pharma achieves preclinical proof of concept for U3-1287 (AMG 888)Antibodies

10 April 2008

Glenmark completes preclinical development for initiating Phase I trials for GBR 500 – a monoclonal antibody for inflammationAntibodies

9 April 2008

CuraGen Advances CR011-vcMMAE into Phase IIAntibodies

9 April 2008

Seattle Genetics Highlights SGN-70 at AAI Annual MeetingAntibodies

9 April 2008

Phase II Study of IMC-A12 for Advanced Head and Neck Cancer Commences Patient EnrollmentAntibodies

9 April 2008

Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA MeetingAntibodies

8 April 2008

U.S. Food and Drug Administration Approves ORENCIA(R) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and OlderAntibodies

8 April 2008

Amgen Statement on Romiplostim PDUFA DateAntibodies

8 April 2008

Seattle Genetics Announces Initiation of Phase Ib Clinical Trial of SGN-40 in Combination with Rituxan and Gemzar for Non-Hodgkin LymphomaAntibodies

8 April 2008

ACZ885, a new biological drug in development, shows potential in treating serious life-long autoinflammatory diseasesAntibodies

3 April 2008

Medarex Announces Ipilimumab Program Continues to Move ForwardAntibodies

2 April 2008

Pivotal Phase 3 Data Show Denosumab Increased Bone Density at Multiple Skeletal Sites in Early and Later Stage Postmenopausal WomenAntibodies

1 April 2008

Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced MelanomaAntibodies

31 March 2008

Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in USAntibodies

31 March 2008

Phase II results for CDP791 in non-small cell lung cancer support further clinical developmentAntibodies

28 March 2008

Seattle Genetics Expands SGN-35 Clinical Program with Initiation of Second Phase I TrialAntibodies

27 March 2008

Trubion Initiates Phase 1/2 Study of TRU-016 in CLL, Announces Next-Generation Product Candidate for RA and Provides Product Pipeline UpdateAntibodies

27 March 2008

Thallion provides update on Shigamabs (R) programAntibodies

26 March 2008

DAIICHI SANKYO Extends Alliance with MorphoSys for Use of HuCAL GOLD to Develop Novel Antibody TherapiesAntibodies

20 March 2008

Zevalin(R) Receives Positive CHMP Opinion in Europe for First-Line Consolidation TreatmentAntibodies

20 March 2008

Seattle Genetics Initiates SGN-33 Clinical Trial in Combination with Revlimid(R) for Myelodysplastic Syndromes (MDS)Antibodies

20 March 2008

CHMP Upholds Negative Opinion for the EU Application for Cimzia® in the Treatment of Crohn’s DiseaseAntibodies

20 March 2008

Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other CancersAntibodies

19 March 2008

MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with AsthmaAntibodies

18 March 2008

Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing SpondylitisAntibodies

17 March 2008

MorphoSys Obtains Agreement for Production of Antibody Material in MOR202 Program with Crucell and DSMAntibodies

17 March 2008

Amgen and Wyeth Announce Updates to U.S. Prescribing Information for Enbrel(R)Antibodies

16 March 2008

GlaxoSmithKline’s Bosatria shows promise in late-stage studyAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

2023 Sales of Recombinant Therapeutic Antibodies, Proteins, Biosimilars & Other Biologics

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

CD73 Inhibitor Pipeline Review

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

ROR1-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

CCR8-Targeted Antibody Immunotherapy Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review